Cthrc1 is a novel immune checkpoint molecule in colorectal cancer
AssigneeMaineHealth
InventorsMichaela Reagan, Volkhard Lindner, Sergey Ryzhov
Life of this patent
Estimating the term…
Abstract
Disclosed herein are Collagen Triple Helix Repeat Containing 1 (CTHRC1) antibodies, including compositions and methods of using said antibodies. The antibody molecules can be used to treat, prevent, and/or diagnose disorders and diseases, such as colorectal cancer and pre-cancerous cells of colorectal cancer.
Claims31
An isolated antibody, or antigen-binding fragment thereof, which comprises:
- 1) a) a heavy chain variable region (VH) comprising an HCDR1 amino acid sequence of SEQ ID NO:
- 5;
- an HCDR2 amino acid sequence of SEQ ID NO:
- 6;
- and an HCDR3 amino acid sequence of SEQ ID NO:
- 7;
- and a light chain variable region (VL) comprising an LCDR1 amino acid sequence of SEQ ID NO:
- 8, an LCDR2 amino acid sequence of SEQ ID NO:
- 9, and an LCDR3 amino acid sequence of SEQ ID NO:
- 10;
- or
- b) VH comprising an HCDR1 amino acid sequence of SEQ ID NO:
- 20;
- an HCDR2 amino acid sequence of SEQ ID NO:
- 21;
- and an HCDR3 amino acid sequence of SEQ ID NO:
- 22;
- and VL comprising an LCDR1 amino acid sequence of SEQ ID NO:
- 23, an LCDR2 amino acid sequence of SEQ ID NO:
- 24, and an LCDR3 amino acid sequence of SEQ ID NO:
- 25,
- wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 are according to Kabat numbering;
- or
- 2) a) a heavy chain variable region (VH) comprising an HCDR1 amino acid sequence of SEQ ID NO:
- 11;
- an HCDR2 amino acid sequence of SEQ ID NO:
- 12;
- and an HCDR3 amino acid sequence of SEQ ID NO:
- 13;
- and a light chain variable region (VL) comprising an LCDR1 amino acid sequence of SEQ ID NO:
- 14, an LCDR2 amino acid sequence of “LAS”, and an LCDR3 amino acid sequence of SEQ ID NO:
- 10;
- or
- b) VH comprising an HCDR1 amino acid sequence of SEQ ID NO:
- 37;
- an HCDR2 amino acid sequence of SEQ ID NO:
- 38;
- and an HCDR3 amino acid sequence of SEQ ID NO:
- 39;
- and VL comprising an LCDR1 amino acid sequence of SEQ ID NO:
- 40, an LCDR2 amino acid sequence of “TT”, and an LCDR3 amino acid sequence of SEQ ID NO:
- 25,
- wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 are according to IMGT numbering;
- or
- 3) a) a heavy chain variable region (VH) comprising an HCDR1 amino acid sequence of SEQ ID NO:
- 15;
- an HCDR2 amino acid sequence of SEQ ID NO:
- 16;
- and an HCDR3 amino acid sequence of SEQ ID NO:
- 7;
- and a light chain variable region (VL) comprising an LCDR1 amino acid sequence of SEQ ID NO:
- 8, an LCDR2 amino acid sequence of SEQ ID NO:
- 9, and an LCDR3 amino acid sequence of SEQ ID NO:
- 10;
- or
- b) VH comprising an HCDR1 amino acid sequence of SEQ ID NO:
- 41;
- an HCDR2 amino acid sequence of SEQ ID NO:
- 42;
- and an HCDR3 amino acid sequence of SEQ ID NO:
- 22;
- and VL comprising an LCDR1 amino acid sequence of SEQ ID NO:
- 23, an LCDR2 amino acid sequence of SEQ ID NO:
- 24, and an LCDR3 amino acid sequence of SEQ ID NO:
- 25,
- wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 are according to Chothia numbering.
-3. (canceled)
The isolated antibody, or antigen-binding fragment thereof of claim 3, wherein the VH comprises an amino acid sequence at least 85%, 90%, or 95% identity to SEQ ID NO:
- 1 or 17;
- or
- wherein the VL comprises an amino acid sequence at least 85%, 90%, or 95% identity to SEQ ID NO:
- 3 or 19.
-12. (canceled)
(canceled)
-22. (canceled)
-26. (canceled)
(canceled)
-37. (canceled)
(canceled)
(canceled)
-49. (canceled)
-53. (canceled)
Dependencies are inferred from the claim text.